Prevent
PREVENT is a Nagoya-based Japanese healthcare technology company that provides online lifestyle disease escalation prevention and medical data analytics to enterprise health insurance unions, municipal governments, and corporations, anchored by Myscope risk-prediction analytics and the Mystar mobile coaching program.
- Company typePrivate
- Founded2016
- HeadquartersNagoya, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Prevent does
PREVENT Co., Ltd. is a Nagoya, Japan-based healthcare technology company founded in July 2016 as a spin-off from the Nagoya University Medical Department. The company focuses on lifestyle disease escalation prevention (重症化予防) — intervening with patients already being treated for hypertension, diabetes, dyslipidemia, and related conditions, a population underserved by Japan's conventional specific health guidance (特定保健指導) framework. Its platform is built around two core products: Myscope, a medical data analytics service that ingests health checkup results, medical receipt (レセプト) data, and qualification records to predict lifestyle and vascular disease onset risk for health insurance unions and municipalities; and Mystar, a fully-online 6-month disease management program combining a dedicated mobile application, wearable monitoring devices (blood pressure, steps, sleep, salt intake via urinalysis), and biweekly one-on-one coaching by medical specialists. Output is delivered entirely online, enabling nationwide reach without in-person visits, and the program reports a 95%+ completion rate.
The business sells primarily on a B2B basis to enterprise health insurance unions (健保組合) and local government National Health Insurance programs, with per-participant fees for Mystar and project/subscription-based fees for Myscope analytics. Supplementing the core platform are online seminars (starting at ¥275,000 per session, ¥550,000/year for the on-demand channel), medical consultation recommendation services, and a newer SaniQara sub-brand launched in November 2025 for musculoskeletal wellness (back pain, shoulder stiffness) that adds AI posture analysis and physiotherapist-led counseling. Revenue also derives from collaborative research and RWD analytics engagements with pharmaceutical companies (AstraZeneca, DISCOVERY, Boehringer Ingelheim, Novartis, Novo Nordisk). Approximately 200 health insurance unions have introduced Mystar, more than 10,000 individuals have been served, and 300,000+ health records are reported in the analytics asset. PREVENT became a wholly-owned subsidiary of Sumitomo Life Insurance in December 2023, with a regional office in Hamamatsu in addition to the Nagoya headquarters, and an internal Insight Lab that publishes peer-reviewed research to underpin evidence-based product development.
Prevent firmographics
Firmographics- Name
- Prevent
- Legal name
- 株式会社PREVENT
- Website
- https://prevent.co.jp
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PREVENT is a Nagoya-based Japanese healthcare technology company that provides online lifestyle disease escalation prevention and medical data analytics to enterprise health insurance unions, municipal governments, and corporations, anchored by Myscope risk-prediction analytics and the Mystar mobile coaching program.
- Ownership category
- akta.pro rank
Prevent industry classification
Industry- Product category
- Preventive Healthcare Software
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD)
- akta.pro secondary industries
- Chronic Condition Virtual Care & Disease Management (Payer-Sponsored) (HLALACAE), Virtual Preventive Care & Wellness Coaching (incl. lifestyle medicine) (HLALADAK), Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI), Employer Wellness & Population Health Programs (HLAEAAAH)
Keywords
Where Prevent is headquartered
LocationHeadquarters
- HQ city
- Nagoya
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Prevent business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Mystar Program Fees: Health insurance unions and corporations pay per-participant program fees for the 6-month lifestyle improvement program. Billed based on the number of enrolled participants. This is the primary revenue stream.
- Myscope Data Analytics Services: Health insurance unions and municipalities pay for medical data analysis services, including risk stratification reports and target identification. Typically project or subscription-based.
- Online Seminar / Training Programs: Fees for wellness seminars, online training content, and educational materials for corporate health management (健康経営). Plans range from Light (¥275,000+) to Premium, plus speaker dispatch at ¥55,000 per session.
- SaniQara Services: New revenue stream from corporate wellness services targeting back pain and shoulder stiffness. Includes assessment reports, seminars, face-to-face advice sessions, SaniQara BOX subscription, and AI posture check events.
- Collaborative Research & Consulting: Fee-for-service research collaborations with pharmaceutical companies, local governments, and universities (e.g., CKD projects with AstraZeneca, HAE project with DISCOVERY, hypertension project in Nagano Prefecture).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | One-time / per event | Light Plan for online seminars |
| Unit Pricing | One-time / per event | Speaker dispatch for seminars |
| Subscription | Annual | On-demand video streaming (annual) |
| Hybrid | Quote-based | SaniQara customized plans |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels8 records
Prevent product offering
Product offeringCore offering
PREVENT sells a data-driven disease-prevention platform to Japanese health insurance unions, municipalities, and employers. Its core services are Myscope (medical data analytics that predict lifestyle and vascular disease risk) and Mystar (an online 6-month coaching program with a mobile app and monitoring devices for high-risk individuals already under treatment). The portfolio is rounded out by SaniQara (corporate musculoskeletal programs for low back pain and shoulder stiffness) and by online health-management seminars.
Product overview
PREVENT operates a platform-plus-modules architecture centered on lifestyle disease escalation prevention. The core offerings are Myscope (medical data analytics for risk prediction) and Mystar (online disease management coaching with monitoring devices), supplemented by online seminars and medical consultation recommendation services. A newer sub-brand, SaniQara, launched in November 2025, extends the portfolio to musculoskeletal health (low back pain and shoulder stiffness prevention) for the working population. Research and evidence generation are handled by the PREVENT Insight Lab division.
Differentiator
Problem solved
Functional benefit
Brands
- SaniQara (サニカラ): A workplace health management sub-brand focused on preventing lower back pain and shoulder stiffness, offering services including assessment reports, online seminars, in-person consultation sessions, SaniQara BOX content delivery, and AI posture check events.
Products and services
- Myscope A medical data analysis service for Japanese health insurance unions (健康保険組合) and local governments that ingests health-checkup results, medical claims (レセプト) data, and other medical data to predict lifestyle-disease and vascular-disease onset risk, score and rank insured persons by future risk, and enable targeted extraction of high-risk individuals for intervention programs.
- Mystar An online, fully-remote 6-month lifestyle-disease escalation-prevention program for individuals already being treated for hypertension, diabetes, dyslipidemia, cerebrovascular disease, or ischemic heart disease. Delivered via a dedicated mobile app with paired monitoring devices (blood pressure monitor, salt-intake urinalysis, Fitbit for activity and sleep), with biweekly 1-on-1 coaching calls from medical specialists; reported 95%+ program completion rate.
- Online Seminar Service (オンラインセミナー) Tiered health-management and collaboration-health seminar package offered in online, in-person, and on-demand video formats covering topics including vascular disease, exercise, diet, sleep, mental health, and women's health; priced from ¥275,000 (Light) per session and ¥55,000 per in-person speaker dispatch, with annual on-demand video subscription available at ¥550,000.
- Medical Consultation Recommendation Service (受診勧奨サービス) A service that promotes early medical consultations to prevent worsening of lifestyle diseases, targeting individuals identified as high-risk through Myscope data analysis and encouraging appropriate medical care-seeking behavior.
- SaniQara (サニカラ) Corporate sub-brand for preventing lower back pain and shoulder stiffness in working populations. Services include assessment reports, physiotherapist-led face-to-face advisory sessions, online seminars, AI posture-check events, and a monthly SaniQara BOX content subscription that combine evidence-based medicine with behavioral-change expertise.
Quantifiable outcome
- 84% of 56 high-risk participants showed lifestyle disease risk factor improvement in Hamamatsu PFS pilot program
- +6 more outcomes
Companies that use Prevent
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
Prevent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Prevent partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered minor, flagship / core and core.
- Ichinomiya City and Nagoya University Hospital (一宮市・名古屋大学医学部附属病院)minorPartnership agreement signed April 6, 2026 for joint research and regional health problem-solving. Aims to maximize healthy life expectancy, work-life expectancy, and quality of life through collective expertise, technology, and assets.
- Novo Nordisk Pharma (ノボ ノルディスク ファーマ)minorPartnered with Shizuoka Prefecture and Izu City to support liver disease severity prevention efforts. PREVENT conducted liver disease-related data analysis for the initiative addressing MASLD/MASH.
- Iwaki City Medical Association / Boehringer Ingelheim (いわき市医師会・ベーリンガーインゲルハイム)minorIwaki Heart Failure Discovery Project: PREVENT collaborated with the local medical association and pharmaceutical company to promote cardiac function testing for at-risk residents. Quantitative evaluation showed increased BNP and NT-proBNP testing rates during the 4-month evaluation period.
- Kochi Prefecture / Kochi University / Novartis Pharma (高知県・高知大学・ノバルティスファーマ)minorPREVENT supported an ischemic heart disease prevention initiative by conducting data analysis, providing medical consultation recommendations, and performing objective program evaluation for Nankoku City's program.
- Nagano Prefecture (長野県)minorPREVENT was commissioned by Nagano Prefecture to support a hypertension management improvement initiative targeting untreated and treatment-interrupted hypertensive patients across all 77 municipalities' National Health Insurance programs.
- Kashima City / Sumitomo Life Insurance (鹿嶋市・住友生命)flagship / coreThree-party comprehensive partnership agreement signed November 2021. Kashima City MVM Healthcare project provides lifestyle disease prevention services to municipal residents. First social implementation case under the tripartite agreement. Won Sports Agency award 2022 and Japan Open Innovation Award 2025.
- DISCOVERY (Hereditary Angioedema Diagnostic Consortium / 一般법인遺伝性血管性浮腫診断コンソーシアム)minorPartnership for rare disease early detection. Using PREVENT's real-world data to validate and improve HAE (hereditary angioedema) diagnostic prediction model developed by DISCOVERY. Validated on Japanese claims data achieving high detection accuracy.
- Kawanishi Town / Kawanishi Sports Club (奈良県川西町・川西スポーツクラブ)minorE-sports for frailty prevention consortium. PREVENT conducted program evaluation for a 3-month e-sports program for active seniors in Kawanishi Town, demonstrating improvements in physical function (TUG, SPPB scores) and cognitive function (MoCA-J).
- Seto City (愛知県瀬戸市)minorPartnership agreement for health and welfare business support. Focus on promoting integrated elderly health services and disease prevention using data-driven approaches.
- Konan Women's University (甲南女子大学)minorAcademic collaboration resulting in peer-reviewed publication (Circulation Reports) on the effectiveness of PREVENT's mobile health program for vascular disease risk reduction. Led by Konan Women's University PT lecturer Masashi Kanai.
- Sugi Holdings / Sugi Pharmacy (スギ薬局)minorCo-hosted wellness webinar with Sugi Pharmacy combining PREVENT's disease prevention expertise with Sugi's specific health guidance experience. Jointly promoted health management education.
- AstraZeneca (アストラゼネカ)minorCollaborative CKD (chronic kidney disease) awareness project with three health insurance unions and PREVENT. Featured in AstraZeneca's i2.JP (Healthcare Open Innovation Network) case studies.
- KDDI Research (KDDI総合研究所)coreKDDI Research collaborated with PREVENT and Hamamatsu City on a public-private Pay-for-Success pilot (August 2021-August 2022) for lifestyle disease prevention among National Health Insurance members. The project validated a new PFS results-based payment model for municipal healthcare cost optimization.
- Hamamatsu City (浜松市)coreMunicipal partnership for National Health Insurance lifestyle disease prevention. Included Pay-for-Success model validation and the 'Hamamatsu Wellness Lab' initiative. PREVENT established a local office in Hamamatsu to support the partnership.
- Sakai City / Sumitomo Life Insurance (堺市・住友生命)minorJoint initiative with Sakai City and Sumitomo Life to provide health promotion and lifestyle disease prevention programs to National Health Insurance members who have not received specific health examinations.
- Unnan City / Sumitomo Life Insurance (雲南市・住友生命)minorThree-party partnership (PREVENT, Unnan City, Sumitomo Life) for regional lifestyle disease prevention and fiscal sustainability. Aims to address health challenges and medical cost increases in the municipality.
- Nagoya University (名古屋大学)coreNagoya University and PREVENT entered a joint research agreement focused on CKD (chronic kidney disease) prevention. The collaboration involves Nagoya University Graduate School of Medicine (Nephrology, Prof. Maruyama), the Preventive Early Medical Care Creation Center (Prof. Adachi), and the Hospital Medical Development Department Data Center. The goal is to build mechanisms for CKD progression prediction and prevention effectiveness measurement using PREVENT's claims and health checkup data.
- MedPeer Group (メドピアグループ)minorBusiness partnership announced September 2018 for collaboration in the health insurance and medical domain.
- FiNCminorBusiness partnership signed March 2017 for service collaboration in the health/wellness domain.
Scale indicators7 records
Recent moves10 records
Expansion highlights6 records
Prevent competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Prevent social profiles
Digital presencePrevent compliance and trust
Trust signalCompliance2 records
Prevent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prevent leadership team
Management profileNumber of profiles
Profiles5 records
Prevent funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prevent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prevent
What does Prevent do?
PREVENT sells a data-driven disease-prevention platform to Japanese health insurance unions, municipalities, and employers. Its core services are Myscope (medical data analytics that predict lifestyle and vascular disease risk) and Mystar (an online 6-month coaching program with a mobile app and monitoring devices for high-risk individuals already under treatment). The portfolio is rounded out by SaniQara (corporate musculoskeletal programs for low back pain and shoulder stiffness) and by online health-management seminars.
Is Prevent a public or private company?
Prevent is a private company. It is classified as corporate owned and is currently operating.
When was Prevent founded?
Prevent was founded in 2016. It employs 11 to 50 people.
Where is Prevent based?
Prevent is headquartered in Nagoya, Japan, in the Asia region.
How does Prevent make money?
Five revenue lines are on record. Mystar Program Fees are the primary driver. The others are myscope Data Analytics Services, online Seminar / Training Programs, saniQara Services and collaborative Research & Consulting.
Does Prevent have an API?
No public API is recorded for Prevent.
What industry is Prevent in?
Prevent's product category is Preventive Healthcare Software. Its primary akta.pro industry code is HLALADAD, Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN), with a secondary code of HLALACAE, Chronic Condition Virtual Care & Disease Management (Payer-Sponsored). Its SIC code is 8000.